(1 - 15 von 28
)
Takeda Highlights Favorable Safety Profile of Entyvio ...
www.finanznachrichten.de
"Long-term remission and a well-established safety profile are key factors when it comes to treating chronic conditions like UC and CD," said Karen Lasch, M.D., Medical Head, GI Specialty, U.S ...
FDA accepts application for subcutaneous Entyvio for Healiowww.healio.com › news › online
www.healio.com
... formulation of vedolizumab,” Karen Lasch, MD, medical head of specialty GI in the U.S. Medical Office at Takeda said in the release. “Takeda ...
FDA approves ointment for precancer skin lesions; Takeda ...Endpoints News
endpts.com
— ... many facets of everyday life are impacted by the symptoms of EoE,” said Karen Lasch, VP, Gastroenterology, US Medical, Takeda.
Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis...
www.takeda.com
“The treatment paradigm for ulcerative colitis is evolving, and further investigation into how to integrate various treatment options may be beneficial for physicians,” said Karen Lasch, M.D., U.S. medical director, Gastroenterology, Takeda. “We believe vedolizumab is an important treatment for patients with ...
sortiert nach Relevanz / Datum